Pfizer Inc’s potential bid for AstraZeneca Plc appeared to be gaining traction following a Pfizer conference with analysts on 28 April and a formal declaration of interest to the London Stock Exchange earlier the same day.
Pharming Group NV has raised €14.7 million with a private placement of its shares and warrants with existing institutional shareholders to support the expected launch of Ruconest, a treatment for hereditary angioedema.
The French biotechnology company TxCell SA has secured €16.2 million in an initial public offering of its shares on the Euronext stock exchange in Paris, enabling it to advance the clinical development of its lead product Ovasave for refractory Crohn’s disease.
Novartis, GlaxoSmithKline Plc and Eli Lilly and Company announced a fundamental reshaping of their businesses on 22 April while yet-to-be denied rumours circulated on global stock markets of an imminent bid by Pfizer Inc for AstraZeneca Plc.
OxThera AB, a privately-held Stockholm-based biotechnology company, has raised SEK 70 million (€7.5 million) to finance clinical development of Oxabact, a treatment for primary hyperoxaluria (PH), a genetic disorder that can lead to kidney failure.
BioAlliance Pharma SA of France has reached an agreement with Topotarget A/S of Denmark to merge, enabling the companies to jointly exploit their oncology portfolios. Shareholders of BioAlliance will hold about two-thirds of the merged company.
Wilson Therapeutics AB, a one-product company created by a Swedish venture capital company, has raised $40 million in a Series B round led by an international syndicate of venture funds.
AAVLife SA, a French start-up company that is using an adeno-associated virus vector to deliver a new gene therapy, has raised $12 million in a series A equity placement led by Versant Ventures Management LLC of Menlo Park, California.
Spinifex Pharmaceuticals Pty, an Australian developer of chronic pain treatments, has raised US $45 million in a Series C financing round from venture capitalists led by Novo A/S of Denmark and the new investor, Canaan Partners of Menlo Park in California.
Edinburgh-based NuCana BioMed Ltd has raised $57 million in a Series B financing round to support the development of cancer medicines that are chemically adapted nucleoside analogues, reportedly with an enhanced ability to trigger cancer cell death.